III

Able_Web3798

Why flyin' high today? This is what I got, let me know..... 1) Today was effectively the deadline for participation/objections in the DEA Schedule III hearing process (and appears no big coordinated opposition?) ... more likely smooth sailiing than not for the June 29 DEA hearing. 2) The Curaleaf uplisting/ADR angle ..... access to more $$$, it was out 1-2 days ago, but coupled with the above, has led to it being more credible.

SPAC_Time

[Factorial and Cartesian Growth Corporation III Announce Approval of Business Combination by Cartesian Growth Shareholders](https://www.globenewswire.com/news-release/2026/05/27/3302458/0/en/factorial-and-cartesian-growth-corporation-iii-announce-approval-of-business-combination-by-cartesian-growth-shareholders.html) \- CGCT CGCTW "[Shareholders holding](https://www.sec.gov/Archives/edgar/data/2049662/000110465926067117/tm2615767d1_8k.htm#:~:text=Shareholders%20holding) 23,051,313 Class A ordinary shares exercised their right to redeem such shares for a pro rata portion of the funds in the Company’s trust account. As a result, $239,964,168.33 (approximately $10.41 per share) will be removed from the Company’s trust account to pay such shareholders. As previously reported, on December 17, 2025, the Company entered into a Stock Purchase Agreement (the “Institutional Investor Stock Purchase Agreement”) with a certain institutional investor (the “Institutional Investor”) and a Stock Purchase Agreement (the “Sponsor Investor Stock Purchase Agreement” and, together with the Institutional Investor Stock Purchase Agreement, the “Stock Purchase Agreements”) with an affiliate of CGC Sponsor III LLC, the sponsor of the Company (such affiliate, the “Sponsor Investor” and, together with the Institutional Investor, the “PIPE Investors”). Pursuant to the terms of the Stock Purchase Agreements, to the extent a PIPE Investor purchases Class A ordinary shares of the Company on the open market, and agrees (i) **not to transfer directly or indirectly such shares until the Closing** and (ii) in the case of the Institutional Investor, to vote such shares in favor of the proposals described above, or, in the case of the Sponsor Investor, to abstain from voting such shares in connection with the proposals described above, it will reduce, on a share for share basis, such PIPE Investor’s purchase obligation under its Stock Purchase Agreement. **The Institutional Investor and the Sponsor Investor elected to satisfy 2,000,000 shares and 1,470,764 shares of their respective purchase obligations through such open market purchases**." "[Class A ordinary shares subject to possible redemption](https://www.sec.gov/Archives/edgar/data/2049662/000110465926062778/tmb-20260331x10q.htm#:~:text=Contingencies%20(Note%206)-,Class%20A%20ordinary%20shares%20subject%20to%20possible%20redemption,-%2C%2027%2C600%2C000%20shares), 27,600,000 shares as of March 31, 2026 " Looks like about 1,077,923 unredeemed and tradeable shares until the closing.

stuenkes

[newcleo, A Developer of Advanced Nuclear Reactors and Nuclear Fuel, to Become Public Company Through Business Combination with NewHold Investment Corp III](https://www.globenewswire.com/news-release/2026/05/27/3301791/0/en/newcleo-a-developer-of-advanced-nuclear-reactors-and-nuclear-fuel-to-become-public-company-through-business-combination-with-newhold-investment-corp-iii.html) [ProLogium, a Next Generation Solid-State Battery Developer with 10+ Years of Proven Commercialization, to List on the Nasdaq through a Merger with Translational Development Acquisition Corp.](https://www.globenewswire.com/news-release/2026/05/27/3301774/0/en/prologium-a-next-generation-solid-state-battery-developer-with-10-years-of-proven-commercialization-to-list-on-the-nasdaq-through-a-merger-with-translational-development-acquisitio.html)

CD274

LUNR recovered because full NASA press release did in fact award them a contract: https://www.ap7am.com/en/127919/moon-base-push-marks-nasas-new-lunar-era?hl=en-US#:~:text=Moon%20Base%20III%20will%20deploy,swirls%20on%20the%20Moon's%20surface.

C130J_Darkstar

NuScale got through the NRC earlier because it’s fundamentally just a Gen III light-water reactor, not a novel Gen IV architecture. The issue was never licensing- it was economics and execution, which is why serious customer momentum largely evaporated after the CFPP collapse. The landscape is shifting now with the ADVANCE Act and DOE RPP efforts creating a far more supportive path for advanced reactors like Oklo. What makes Oklo compelling is the vertically integrated power-as-a-service model, fuel and recycling strategy, and focus on scalable fleet deployment rather than simply selling reactors. If they execute on the 2027/2028 timeline, the first-mover advantage could end up being massive.

SPAC_Time

[CPRO, a Leader in the Physical AI Security Industry, to be Publicly Listed on a U.S. National Securities Exchange Through Business Combination with Lakeshore Acquisition III Corp.](https://www.prnewswire.com/news-releases/cpro-a-leader-in-the-physical-ai-security-industry-to-be-publicly-listed-on-a-us-national-securities-exchange-through-business-combination-with-lakeshore-acquisition-iii-corp-302781369.html) \- LCCC LCCCR LCCCR = right that entitles the holder thereof to receive one-sixth (1/6) of one Ordinary Share upon consummation of the Company’s initial business combination

buttermilkmeeks

Factorial Batteries it is IPOing via Cartesian Growth III SPAC under the ticker CGCT (for a few more weeks) and will become FAC

drytexterfinalboss

Self defense strike here and self defense strike there Before you know we get a self defense world war III LMAO 🤌

dljmonkeyboiz

Al bin sulamin III said they just got there though

MatrixOrigin

>“We fundamentally disagree with the court’s decision today. All parties demonstrated substantial injury that exceeds the threshold required by Article III,” SAM President and CEO Kevin Sabet said. GTFO 🤡

Total_Schedule591

Arthritis III

Silver_Variety_1108

I was a young investor back then and made more than my share of mistakes. Now, I try to get into new growing sectors. I got into 2 drone stocks in 2024 and they have 6x. Now, today I think $DRTS a small, unknown Biotech that has found a better way to treat solid cancer tumors. They already have been approved for Head &Neck cancer in Japan. They have shown very little side effects because their targeted therapy kills the cancer, but not the surrounding healthy tissue. In brain cancer, they showed 100% control at 67% complete responses. In skin cancer, it’s nearly 100% effective. They are starting with Pancreatic cancer. The best part is, their treatments do not impair the immune system like chemotherapy and full body radiation does. I also like $SLS! They have 2 drugs for AML. Their phase III regal trial has gone on much longer than expected. That is a great sign because it shows patients are living longer.

King_Chron

Don't buy into the media panic on this one. TerrAscend didn't just mess up their taxes, this is actually a calculated move in a massive game of chicken between the weed industry and the feds. The cash flow strategy here is wild. Since cannabis companies can't get normal bank loans, they usually have to go to predatory lenders who charge crazy interest rates like 15 percent or more. Instead, these companies realized they could file amended tax returns, get an automatic refund check from the IRS, and immediately cash it. Even if the IRS comes back years later demanding the money back with standard interest, that federal underpayment rate is only around 7 percent. The MSOs basically figured out how to use the IRS as a cheap bridge loan to keep scaling their businesses. TerrAscend's 8.3 million is nothing compared to the bigger picture. Publicly traded operators are sitting on something like 1.6 billion dollars in contested 280E taxes right now. Trulieve has nearly 450 million on the line, Verano has almost 380 million, and Cresco is around 170 million. The IRS is sweating because if they don't fight TerrAscend immediately, every major operator is going to walk away from their old tax bills. The top law firms representing these companies actually want this fight. They are using these refund demands to drag the IRS into court, hoping a federal judge will finally rule that 280E is an unconstitutional burden on state legal businesses. Now that the feds are moving cannabis to Schedule III, 280E is going away for future taxes anyway, so the whole war right now is over the past. The industry is basically arguing that because the government now admits cannabis has medical value, they never should have been paying those insane tax rates in the first place. TLDR: The big weed companies triggered these lawsuits on purpose to force a definitive court ruling. They are betting that federal judges or the new Schedule III rules will wipe out their old tax debts before the IRS can actually force them to pay.

JellyfishFestival

One of the many problems with the SpaceX IPO is how the company has to develop most of the technologies and processes to be fantastically profitable. They don't currently exist, or exist at any commercially profitable scale. Doing that requires time, innovating things that don't exist, waiting on pre-requisite technologies, and most importantly for investors...massive amounts of capex and dilution to fund that capex. It's like valuing Nvidia as a $2T company back in 1999 when it was making graphics chips for Pentium III towers but a sci-fi mag talked about the idea of super intelligent robots.

Magikarp_to_Gyarados

>He pays other people to come up with ideas, buys them or steals them, then takes credit.  That's more or less the same as Steve Jobs. Before Apple, Steve Jobs worked at Atari. Atari co-founder Nolan Bushnell challenged Jobs to create a video game called "Breakout" using a small number of chips. Bushnell offered Jobs something like $750 for the project, and a $5000 bonus for designing the game with a small number of chips. Jobs convinced Wozniak to design the game, giving him half of the $750 fee. However, Jobs kept the $5000 bonus for himself and never told Wozniak of its existence. Wozniak only found out about the deception many years later. >He isn't a visionary and most of his actual ideas like Optimus and Cybertruck are half baked, shitty and poorly executed. The same could be said of many Apple products during Jobs' first tenure. Apple III was a dud. Same with the Lisa workstation. Many of the early Macintosh machines were underspec'd. The talking Mac demo was a customized machine that wasn't representative of the actual consumer product. The original MacOS itself was a crufty mess that hampered Apple until the entire codebase was thrown out for OS X in the early 2000s.

Hot_Set597

Tomorrow is **El Día del Toro** in Spain — a centuries-old tradition where the entire country honors the bull. Dating back to 1387, Spanish law mandates that any stock with "bull" in the name must open 10% higher on this sacred day. Charles III wrote it into law in 1764 after a bull saved his favorite horse from a wolf. The horse's name was Webull. $BULL. You've been warned.

WinstonSalemSmith

Superman III, Richard Pryor

RJ5R

Who stands to profit? The suppliers, distributors, retail, all 3? How can we get in on this trade? [https://www.reddit.com/r/oil/comments/1tfvbqp/motor\_oil\_is\_the\_next\_shortage\_and\_its\_just\_as/?sort=new](https://www.reddit.com/r/oil/comments/1tfvbqp/motor_oil_is_the_next_shortage_and_its_just_as/?sort=new) The summary: Shell's plant in Qatar was hit by Iran taking it offline for what could be 2 years. They refine the base formulation for both MOBIL1 and Pennzoil. Other plants hit as well. In total, around \~55% of the US Group III base oils come from gulf region and the current output is 0. Toyota, Nissan, Autozone, and others began to sound the alarm as early as mid April. We are now 1 month after that initial alarm and the shortages of 0W-16 and 0W-8 are imminent. You can do some "diluting" to stretch supply using 0W-20 as a temporary measure, so they're saying that eventually this could also cause 0W-20 prices to spike as well. O'Reilly's has already stopped bulk purchases of 0W-16 and 0W-8. If you drive any vehicles that use these grades of oil, I highly suggest you go and buy enough to get you through the rest of the year maybe even through next year. The Walmart near me only had 4 jugs left of 0W-16

RJ5R

Who stands to profit? The suppliers, distributors, retail, all 3? How can we get in on this trade? [https://www.reddit.com/r/oil/comments/1tfvbqp/motor\_oil\_is\_the\_next\_shortage\_and\_its\_just\_as/?sort=new](https://www.reddit.com/r/oil/comments/1tfvbqp/motor_oil_is_the_next_shortage_and_its_just_as/?sort=new) The summary: Shell's plant in Qatar was hit by Iran taking it offline for what could be 2 years. They refine the base formulation for both MOBIL1 and Pennzoil. Other plants hit as well. In total, around \~55% of the US Group III base oils come from gulf region and the current output is 0. Toyota, Nissan, Autozone, and others began to sound the alarm as early as mid April. We are now 1 month after that initial alarm and the shortages of 0W-16 and 0W-8 are imminent.

type_error

How about Ebola III?

Jerikolol

there's another bullish upside for RELX/WKL? theres the **EU AI Act** thats being discussed in september afaik. Its important because in Annex III of the Act, AI systems utilized in the "Administration of Justice and Democratic Processes" are explicitly classified as High-Risk. This would ad a bunch of new rules and oversight + obligatory human in the loop obligations, which could make it too much of a hassle for claude for example to want to comply with, or ad so much extra friction, that it could be 'regulated out'. Which obviously would be quite bullish for RELX/WKL, who dont have these issues. TBD how this develops.

justinwfreed

Here's a couple that fit into the "advanced materials" sector but also fit into today's push into photonics. ALMU - currently transitioning from R&D to commercialization, their quantum dot photo detectors utilize III-V semiconductor materials made of Indium and gallium arsenide grown on a Si substrate. LWLG - These people have a proprietary polymer that achieves extremely high electro-optic (EO) coefficients that can "modulate" light (sort of like modulating RF) at very high speeds with very low energy consumption. Not quite as far along commercialization-wise as ALMU but certainly worth checking out.

Visual-Try-8081

Isn't GTBIF profitable? Or HITI? I don't buy the “not profitable” argument. GTBIF has a $300 million cash war chest and very little debt. How did they achieve that if they’re not profitable? There are companies in the market that lose money or generate only a small fraction of that revenue, yet still have insane valuations. GTBIF is trading at only a 1.3x valuation. This isn’t about profitability. This is about OTC, MSOS ETF, short selling, options, and manipulation. I’ll patiently wait for Schedule III and uplisting. After that, we’ll see how it works out. For now, I’m just holding the stocks and obviously not buying options.

Silver_Variety_1108

I think some selective Bio Tech stocks will outperform. Specifically $SLS for 2 AML drugs (GPS and SLS009). As they have shown to keep patients alive much longer vs current standard of care. Regal Phase III is nearing its completion and all the research is showing a very high probability of success. Also $DRTS is showing great results in reducing Solid tumor cancers. They are in 5 trials, all showing great effectiveness in shrinking tumors and in some cases eliminating cancer completely. They inject radiation directly into the cancer tumor. This way, the cancer is killed, but the surrounding healthy tissue remains intact. This way, fewer side effects vs chemotherapy and full body radiation. They are already approved for Head and Neck cancer in Japan. They are farthest along in skin cancer. They report on Pancreatic cancer in about a week.

Impossible_Use_9194

Hyperscale Data, Inc. (GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. ​1. The Big News: $5 Million Premium Tender Offer ​The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. ​The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). ​The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. ​Timing: The buyback will formally launch once the company files its Q1 10-Q report. ​2. Preliminary Q1 Earnings & Delay ​Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: ​Revenue: Up roughly 76% year-over-year to $44 million. ​Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. ​3. Expansion Into Intelligent Robotics ​Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. ​4. Progress on Michigan 300 MW AI Compute Campus ​The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. ​5. Bitcoin Treasury Update ​The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. ​What to Watch Next ​Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

RD_006

Think of how stupid the average person is, and realize half of them are stupider than that. (C) George Warren Carlin Buffet III The Esquire

Impossible_Use_9194

(GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. 1. The Big News: $5 Million Premium Tender Offer The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. Timing: The buyback will formally launch once the company files its Q1 10-Q report. 2. Preliminary Q1 Earnings & Delay Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: Revenue: Up roughly 76% year-over-year to $44 million. Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. 3. Expansion Into Intelligent Robotics Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. 4. Progress on Michigan 300 MW AI Compute Campus The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. 5. Bitcoin Treasury Update The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. What to Watch Next Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

Impossible_Use_9194

Hyperscale Data, Inc. (GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. ​1. The Big News: $5 Million Premium Tender Offer ​The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. ​The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). ​The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. ​Timing: The buyback will formally launch once the company files its Q1 10-Q report. ​2. Preliminary Q1 Earnings & Delay ​Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: ​Revenue: Up roughly 76% year-over-year to $44 million. ​Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. ​3. Expansion Into Intelligent Robotics ​Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. ​4. Progress on Michigan 300 MW AI Compute Campus ​The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. ​5. Bitcoin Treasury Update ​The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. ​What to Watch Next ​Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

Impossible_Use_9194

Hyperscale Data, Inc. (GPUS) has experienced an incredibly busy week, marked by major corporate announcements, a massive stock surge, and critical updates regarding its AI data center operations. ​1. The Big News: $5 Million Premium Tender Offer ​The company announced its intent to launch a cash tender offer to repurchase up to $5,000,000 of its Class A Common Stock at $0.21 per share. ​The Premium: This offer price sits well above its recent trading range (~$0.12–$0.14). ​The Reason: Executive Chairman Todd Ault III stated there is a "material disconnect" between the market price and the company's actual asset value. Management reports that its net book value per share is $0.26 based on holding nearly $94 million to $100 million in combined cash, restricted cash, and Bitcoin. ​Timing: The buyback will formally launch once the company files its Q1 10-Q report. ​2. Preliminary Q1 Earnings & Delay ​Alongside the buyback news, Hyperscale Data filed a Form 12b-25 to delay its official Q1 2026 earnings report, but it provided a preliminary snapshot of its financials: ​Revenue: Up roughly 76% year-over-year to $44 million. ​Net Loss: Tracking at approximately $30 million, primarily driven by a $12 million charge related to fluctuations in digital asset prices. ​3. Expansion Into Intelligent Robotics ​Its subsidiary, Omnipresent Robotics, signed a major deal with AGIBOT to acquire up to 143 intelligent robots. Hyperscale Data has allocated a 100,000-square-foot portion of its Michigan Data Center to serve as a U.S. hub for robotics data collection, teleoperation bays, and AI training models. ​4. Progress on Michigan 300 MW AI Compute Campus ​The company reported heavy customer interest in leasing AI compute infrastructure at its Michigan facility. It has already paid for the initial equipment to support its first 30 MW buildout and is evaluating long-term expansion plans to scale the campus past 300 MW of total capacity. ​5. Bitcoin Treasury Update ​The company confirmed its current digital asset holdings stand at 686.72 Bitcoin, which are securely held via its subsidiaries Sentinum and Ault Capital Group. ​What to Watch Next ​Management is expected to hold a conference call on or around May 20, 2026, to officially release its full Q1 results and lay out its upcoming capital market and treasury initiatives.

SPAC_Time

[Cantor Equity Partners III Shareholders Approve Business Combination with AIR](https://www.reddit.com/r/Spacstocks/comments/1tcw9se/cantor_equity_partners_iii_shareholders_approve/) \- CAEP Shareholders approved on May 12. "In light of receipt of the requisite approvals by CAEP Shareholders described above, CAEP expects the Business Combination to be completed promptly following the satisfaction or waiver of the other conditions to the consummation of the Business Combination."

LittlePlacerMine

The rescheduling for medical has already occurred. DEA is holding hearings on non-medical next month and there is a bill in the house that would grant adult use non medical schedule III status. (Not a given some of the house are anti cannabis) But the schedule III for medical is a big win for the big 3 cannabis companies, their tax relief is hundreds of millions. I think the big institutions are holding back waiting for a safe harbor ruling/memo. Otherwise the big banks can’t hold their shares for them.

InfinitelyFinite212

TLDR: * Cannabis was partially moved to Schedule III * This mainly applies to FDA-approved cannabis drugs and state medical cannabis businesses * Recreational/adult-use cannabis is still Schedule I * Medical operators may get 280E tax relief starting in 2026 * Medical operators must register with the DEA * This does not federally legalize cannabis * This does not fix banking or pass SAFE Banking * DOJ is still reviewing whether all cannabis, including adult-use, should move to Schedule III * Legal challenges are likely

PhysicalConsistency

The hell are you talking about? It's been pumping for a decade. The DJIA was 17,540 on May 9, 2016. It's hovering around 50k today. That has nothing to do with China's oil supply or Hormuz or AI or anything else. Even if the AI bubble popped tomorrow, even if WTI spiked to $150/barrel, even if a comet was on a direct course for earth, it will continue to pump until world war III destabilizes the governments which are enabling this inflation stashing. We learned the worst lesson from the great recession, and that lesson was that shit doesn't have to go down if we don't want it to.

BeebleBoxn

Something, something, something, something. No apocalypse, No world War III, No giant asteroid, yeah same old shit in one big loop.

BrightViolinist2362

$DNMXW Dynamix III warrants with some volume today, its been trading weirdly last couple of weeks, big bidder keeps showing up with 30-50k on bid then disappears.

vakr001

Options ARE hard… 1) Most retail investors shouldn’t touch them. Only in the past 10 - 15 years have they become more popular. 2) You need to have a strategy in place, do your homework, and be void of ALL emotion. This is extremely hard. 3) *One minute you're up half a million in soybeans and the next, boom, your kids don't go to college and they've repossessed your Bentley.* Louis Winthorpe III. This quote is so true for Options.

AVBforPrez

That's JP Morgan Chase III, didn't you realize?

KingoftheWildlings

I just need a little World War III action with a hint of bubonic plague, and a new chair of federal reserve who HATES growth and my puts will print

Opening_Normal

Or people realized that Schedule III won't actually help the MSOS much...

CumomEileen

I still don’t get it tbh, what difference does it make to MMs if a stock is trading at $400 or $80 with the same market cap? Garcia III said it was about making the stock more affordable for employees which sounds like total BS so I want to understand what his agenda really is

Thumbszilla

They had a revenue miss (approximately 6.2%) but had positive forward-looking guidance regarding Schedule III reclassification, which is expected to drastically improve future earnings by eliminating the 280E tax burden. Bullish!

Thumbszilla

MSOS holding CRLBF earnings report: https://investors.crescolabs.com/news/news-details/2026/Cresco-Labs-Reports-First-Quarter-2026-Financial-Results-Advances-Multiple-Growth-Initiatives/default.aspx They had a revenue miss (approximately 6.2%) but had positive forward-looking guidance regarding Schedule III reclassification, which is expected to drastically improve future earnings by eliminating the 280E tax burden.

MatrixOrigin

**First Quarter 2026 Highlights** * First quarter revenue of $151 million. * Gross profit of $75 million. Adjusted gross profit 1 of $77 million; and an Adjusted gross margin 1 of 50.7%. * SG&A of $54 million or 36.0% of revenue. Adjusted SG&A of $51 million or 33.7%. * Net loss of $17 million. * First quarter Adjusted EBITDA 1 of $33 million and Adjusted EBITDA margin 1 of 21.7%. * Retained the No. 1 share position in multiple billion dollar markets. 2 **Subsequent to Quarter End** * Was conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations. * Opened two new Ohio dispensaries: Bridgeport on April 10, 2026, and Aberdeen on May 5, 2026. * Began supporting operations of nine Pennsylvania dispensaries under a management services agreement. * The Trump Administration reclassified medical marijuana to Schedule III under the Controlled Substances Act, a step that is expected to eliminate the application of Section 280E to Cresco's medical operations; Attorney General Blanche announced an expedited process to review the classification of marijuana more broadly, with a hearing beginning on June 29, 2026. Conference call webcast link: https://events.q4inc.com/attendee/843035052

MatrixOrigin

**Q1 2026 Financial and Operational Highlights** *Revenue of $287 million, with 92% of revenue from retail sales. *Achieved gross margin of 59%, with GAAP gross profit of $170 million. *Reported positive net income attributable to common shareholders of $2 million. Adjusted net income of $20 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations. *Achieved adjusted EBITDA of $100 million*, or 35% of revenue. *Generated cash flow from operations of $56 million and free cash flow of $42 million*. *Cash at quarter end was $353 million. *Closed $60 million private placement of senior secured notes due 2030. *Grew rewards program to 1 million members. *Opened three dispensaries in DeLand, Fort Myers, and Lake Wales, Florida. *See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics **Recent Developments** *The Trump Administration reclassified medical marijuana to Schedule III under the Controlled Substances Act. Attorney General Blanche announced an expedited process to review the classification of marijuana more broadly with a hearing beginning on June 29, 2026. *Filed applications to register state licensed medical marijuana operations including 206 retail locations with the Drug Enforcement Agency. *Opened four dispensaries in Belleview, Boca Raton, Lutz, and Tallahassee, Florida. *Currently operate 240 retail dispensaries and over four million square feet of cultivation and processing capacity in the United States. Conference call webcast link: https://app.webinar.net/V4aBbNBbdmE

Visual-Try-8081

GTI **Highlights for the first quarter ended March 31, 2026:** * Revenue of $300.2 million, an increase of 7.4% over the same period in the prior year. * Cash at quarter end totaled $344.5 million. * GAAP net income of $15.4 million or $0.07 per basic and diluted share. * Normalized EBITDA of $93.5 million or 31.2% of revenue. * Cash flow from operations of $76.0 million. * Repurchased approximately 6.0 million of the Company's Subordinate Voting Shares for $33.3 million. * Increased syndicated credit facility by $50.0 million. **Subsequent to Quarter End** * Conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations. * Repurchased approximately 7.4 million additional Subordinate Voting Shares, bringing 2026 year-to-date repurchases to approximately 13.4 million Subordinate Voting Shares for approximately $77.7 million. Since initiating its share repurchase programs in September 2023, the Company has repurchased approximately 29.0 million shares for approximately $200.0 million. * Submitted registration applications with the U.S. Drug Enforcement Administration for certain state-licensed medical cannabis operations following the federal rescheduling of medical cannabis to Schedule III under the Controlled Substances Act.

MatrixOrigin

**Highlights for the first quarter ended March 31, 2026:** * Revenue of $300.2 million, an increase of 7.4% over the same period in the prior year. * Cash at quarter end totaled $344.5 million. * GAAP net income of $15.4 million or $0.07 per basic and diluted share. * Normalized EBITDA of $93.5 million or 31.2% of revenue. * Cash flow from operations of $76.0 million. * Repurchased approximately 6.0 million of the Company's Subordinate Voting Shares for $33.3 million. * Increased syndicated credit facility by $50.0 million. **Subsequent to Quarter End** * Conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations. * Repurchased approximately 7.4 million additional Subordinate Voting Shares, bringing 2026 year-to-date repurchases to approximately 13.4 million Subordinate Voting Shares for approximately $77.7 million. Since initiating its share repurchase programs in September 2023, the Company has repurchased approximately 29.0 million shares for approximately $200.0 million. * Submitted registration applications with the U.S. Drug Enforcement Administration for certain state-licensed medical cannabis operations following the federal rescheduling of medical cannabis to Schedule III under the Controlled Substances Act.

Knarre30

Hear me out. Lets declare WW III and immediately declare victory. No country will be harmed cause Europe and China will just think he's a moron. But this would cause spy to pump to 1000.

ai-moderator

#TLDR --- Ticker: TMC Direction: Up Prognosis: Buy Shares and hold long-term (Targeting $16 fair value) Business Model: Vacuuming potato-sized battery rocks off the bottom of the ocean 🥔🌊 Geopolitical Vibe: 'Murica desperately needs an independent supply of critical metals (Copper, Nickel, Cobalt, Manganese) so China doesn't choke out our AI and EV dreams. Why it might print: Currently trading at an abysmal 9% of NAV while sitting on the only SEC-compliant deep-sea reserve. Major upcoming catalysts include Trump EO 14285 backing, NOAA permits, and potential DPA Title III government funding. (Or it goes to zero, lol).

Quiet_Deer_4887

But which part (pre, during, post blackout) of which movie (I, II, III) are we in and who get's sh\*tted on the least but does the most? Pretty sure u don't wanna be MU. And GOOG just does nothing most of the time.

throwaway9gk0k4k569

Scuze me. The K6II and K6III were pretty decent. Then Intel went all Rambus RAM when Slot 1 came out. Fuck Intel and Rambus for that one. The early Slot A CPUs were okay but definitely slacked off hard later. AMD had the first multi-core CPUs for quite awhile because Intel refused to compete and give users better CPUs. Remember when Intel voluntarily gave AMD like 1BILLION dollars because they were caught red-handed bribing Dell to only use Intel? And that instruction set you're running right now? It's called AMD64 (NOT x86-64) because Intel, AGAIN, tried to monopolize the market with their shitty Itanium/IA64 instruction set but nobody fell for that shit. Bulldozer years were definitely shit though. Intel finally stopped dragging their ass against the concrete with Sandy Bridge, at least for awhile. Don't even get me started.

ModeForJoe

Earth: World War III Markets: slightly bullish 2028 Elections: "Maybe we should try medicare for all!?" Markets: Socialism!?!?1?!? Sell! Sell! Sell!

the-revenge-trader

At this point even World War III will be a catalyst for the stock market to hit new ATH

Any_Pomegranate1134

# FTC — First Trust Large Cap Growth AlphaDEX Fund * **What it does**: This is an **ETF** (exchange-traded fund), not an operating company. It tracks an index of large-cap growth stocks selected via a proprietary "AlphaDEX" methodology for potential outperformance (positive alpha/risk-adjusted returns) relative to traditional benchmarks. It invests in NASDAQ-listed large-cap growth names. * **What's moving it**: Broad market sentiment, especially large-cap growth/tech performance (e.g., influenced by rates, AI/tech earnings, rotation). Recent performance has been solid YTD but tracks general equity markets with lower volatility than individual small-caps. Small daily moves typical for an ETF. # SIVE — Sivers Semiconductors AB (publ) (NASDAQ Stockholm: SIVE; OTC: SIVEF) * **What it does**: Semiconductor company developing and selling chips, components, modules, and subsystems. It operates in **Wireless** (e.g., 5G mmWave RFICs, beamformers for networks, radar, SATCOM) and **Photonics** (III-V compound semiconductor lasers for optical communication, AI data centers, sensing/LiDAR). Key focus on high-performance, energy-efficient solutions for AI optics, telecom, and defense. * **What's moving it**: Strong momentum tied to **AI data center optics** and photonics boom. Recent catalysts include partnerships (e.g., Jabil for LRO modules), commercialization progress, NASDAQ listing plans via share raise, and hype around its role in AI infrastructure (lasers for high-speed optical links). The stock has seen massive volatility and gains (e.g., sharp multi-day surges) on volume, with AI/supply chain narratives driving retail/institutional interest. # QE — IQE plc (London: IQE) * **What it does**: Global supplier of advanced **compound semiconductor wafer** products and materials. Segments include Wireless (RF for comms/handsets), Photonics (lasers/sensors for light transmission/detection), and CMOS++ (hybrid silicon-compound tech). Used in wireless, AI/data centers, defense, sensing, and more. * **What's moving it**: Recent **capital raise** (strategic partner investment, placing, retail offer) for growth/strategic review. Demand drivers include defense, AI, data centers, and handsets. Positive updates on earnings potential and sector tailwinds (compound semis for next-gen tech), though dilution from raises can pressure price short-term. Volatile small-cap with big swings on funding/news. # KOPN — Kopin Corporation (NASDAQ: KOPN) * **What it does**: Develops and sells **microdisplays**, optics, subassemblies, and related components (AMLCD, LCOS, OLED, emerging MicroLED). Applications in defense (e.g., helmet-mounted displays, weapon sights, drone goggles), enterprise/industrial headsets, medical, training/simulation, and consumer AR/VR wearables. Expanding into AI infrastructure with optical interconnects. * **What's moving it**: High volatility on **AI + defense catalysts**. Recent drivers include a $15M development order/collaboration with [Fabric.AI](http://Fabric.AI) for MicroLED-based optical interconnects (addressing AI data center power/bandwidth bottlenecks), $3.2M+ contract for FPV drone goggles (new market entry), analyst upgrades/reinstatements (Buy ratings, higher targets), and broader defense orders. Strong volume and price runs (new highs) on these news flows; classic small-cap story stock.

1_FCKTRD

*1\_FCKTRD • 2mo ago* *From Kevin Sabet - "Now that doesn't mean that there may not be medical therapeutic effects of the marijuana plant that we should study and that we should have."* *This sounds like Schedule III to me.* [https://x.com/learnaboutsam/status/2025959793517527292?s=20](https://x.com/learnaboutsam/status/2025959793517527292?s=20) What a WhackJob.

Valkorion335786

Some fans have taken to celebrating “the Revenge of the Fifth” on the day following May 4. The name of this “holiday” is of course inspired by Episode III, Revenge of the Sith. May 5th is, therefore, for fans whose allegiances lean more toward the dark side of the force.

newbrevity

They all think Kamala was going to start world war III. Since every accusation is a confession, I can honestly say I don't think things have even begun to get as bad as they're going to yet

creemeeseason

QURE news: Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential Phase III design and analysis plan for AMT-130 four-year data ~ ~ uniQure actively pursuing additional ex-US regulatory pathways to support potential registration of AMT-130 in international markets ~

DeezSpicyNuts

And stepping forth thus, Chauncey Networth Butterchurn IV, with many witnesses present and many eyes upon his person in that very moment, slapped Nigel Chaddington Dickburn III with a supple calfskin glove and challenged him to mortal combat. “Whose mans is this?” Dickburn exclaimed. 

leshermes

Queen Elizabeth came to visit back in 2007, months later the Great Recession had begun.... yesterday, King Charles III came to visit to give a warning... history doesn't repeat itself, but it does rhyme.

AverageNo130

# 📊 Simple Ranking Summary **Most leverage to Schedule III:** 1. Green Thumb 2. Trulieve 3. Curaleaf **Next wave:** 4. Verano 5. Cresco 6. TerrAscend **Smaller impact:** 7. Jushi 8. Ascend **Least benefit:** 9. Planet 13 10. Glass House

Subspace13

There seems to be an increase in combat flights from the UK, Netherlands, Italy, Norway/Oslo, etc. Bunch of Chinooks from Netherlands, 4-5 fighter jets from UK, Italy has a Northrop Grumman RQ-4D Phoenix patrolling Russia's southern border, Norway/Oslo with a Boeing C17A Globemaster III in the sky. Some heightened activity going on.

King_Chron

The SunStream joint venture contributed a profit and higher other comprehensive income, lifting the investment segment * **SunStream restructuring progress**: As U.S. cannabis rescheduling gains momentum, the restructuring of the Parallel and Skymint investments continues to advance toward completion, with only a limited number of remaining requirements outstanding. * As of March 31, 2026, the Company has deployed capital to a portfolio of cannabis-related investments with a carrying value of $410.1 million, including $395.4 million to SunStream Bancorp Inc. (“**SunStream**”). This carrying value was increased by $12.5 million during the first quarter of 2026, primarily due to an increase in the USD to CAD exchange rate from 1.3706 on December 31, 2025 to 1.3939 on March 31, 2026. * The previously disclosed restructuring process relating to Skymint continues. On April 1, 2026, the Michigan Supreme Court has agreed to hear oral argument on applications for leave to appeal. The Court has not reached a decision on the merits. Timing and outcomes remain uncertain and are subject to court process and other factors. * The previously disclosed restructuring process relating to Parallel continues. On February 4, 2025, the Florida Department of Health approved the transfer of Parallel’s license, representing an important milestone in completing Parallel’s restructuring process. In December 2025, a settlement was reached resolving the final remaining litigation, and SNDL currently expects the strict foreclosure process to close in Q3 2026, subject to completion of remaining steps, satisfaction of applicable conditions, and any required approvals. * The investment portfolio generated a positive operating income of $2.0 million in the first quarter of 2026, primarily driven by interests earned from our cash accounts. * On April 23, 2026, the DOJ and DEA issued an order placing FDA-approved cannabis products and state-regulated medical cannabis in Schedule III, while launching an expedited process to reschedule all cannabis from Schedule I. This move is expected to eliminate 280E tax burdens, expand research, improve regulation, and enhance access to capital, strengthening the industry outlook, with direct relevance to SNDL given its exposure to core US medical markets through its SunStream credit exposure.

volckerwasright

"Following President Trump’s Executive Order directing the Office of the Attorney General to expedite the process of rescheduling medical marijuana to Schedule III of the Controlled Substances Act (CSA), the U.S. Department of Justice has published the following regulatory actions in the Federal Register: A final rule placing both FDA-approved medical products containing marijuana and medical marijuana products regulated by a state medical marijuana license in Schedule III of the CSA. A proposed rule withdrawing the prior administrative hearing process. A new notice of hearing, reinstating the formal evidentiary process required under the CSA. The process is being carried out through the formal rulemaking process, which includes public input, administrative review, and potential hearings." https://www.dea.gov/marijuana-rescheduling-regulatory-actions

daedalus_dance

King Charles III dropping constant truth bombs on the Ameripeasants. Without us you'd all be speaking french.

King_Chron

*Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the Company’s ability to execute its go-forward strategy; risks related to additional financing;* ***risks relating to the Company’s debt obligations and the ability to make payments on existing indebtedness;*** *risks related to the ability to access private and public capital; stock market volatility; the availability of financing; changes in the business activities, focus and plans of the Company and the timing associated therewith;* ***the timing of any changes to federal laws in the U.S. to allow for the general cultivation, distribution, and possession of cannabis; regulatory and licensing risks;*** *changes in cannabis industry growth and trends; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation, including the Company’s interpretation of such regulation; public opinion and perception of the cannabis industry; and the risk factors described in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile at www.sedarplus.ca.* ***The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect operations and financial performance.*** **No Formal Warning**: Fluent Corp (formerly Cansortium) has **not** received a formal auditor's going concern warning in 2026. * **Recent Stability Measures**: * **Emergency Funding**: On **March 18, 2026**, the company secured a **$6 million** term loan at a **13.00% PIK interest rate** to strengthen its balance sheet and fund working capital. * **Asset Sale**: It completed a **$12.5 million sale** of its Pennsylvania operations on December 31, 2025, specifically to reduce debt. * **The Federal Reform Link**: The company frames its future viability around **federal rescheduling (Schedule III)**, which it expects will provide massive **280E tax relief** and improve banking access.  FLUENT Corp. +4

SuzyCreamcheezies

An interesting little detail I found while browsing a [law firm's post](https://www.sheppard.com/insights/blogs/dojs-april-2026-cannabis-order-what-it-does-and-what-it-does-not-do) on schedule 3. "This order amends 21 CFR 1312.30 to add FDA-approved marijuana products and state-licensed medical marijuana to the list of nonnarcotic Schedule III through V controlled substances subject to the import and export permit requirement. DEA-registered operators will be eligible to apply for import and export permits, opening access to international markets for the first time." Who thinks we see MSOs applying for international export permits (and retooling for GMP certification)? And LPs applying to import from their Canadian facilities? Something to watch.

ShittyUsernane1222

King Charles III is distracting 🥭 while his majesties red-coats march on Washington and Wall Street.

OkBowls

Oil Wars: Episode III - Revenge of the Emerites The Separatist blockade of the Strait of Hormuz has finally done what years of Senate negotiations could not - shattered the Producers’ Cartel from within. The Emirates of Abu Dhabi, a founding member, is withdrawing effective next month after weeks of Separatist missile strikes and complete abandonment by their Cartel allies. Chancellor Trump has been clear: the Republic’s clone army defends no one for free. The Emirates listened. The Cartel is fracturing, the hyperspace lanes are blockaded, and the Chancellor grows stronger by the day. The Senate did not see this coming. It should have.​​​​​​​​​​​​​​​​

Thumbszilla

From Gemini: The outlook for the AdvisorShares Pure US Cannabis ETF (**MSOS**) is currently dominated by a rapid-fire series of regulatory and financial milestones. Here are the key upcoming catalysts scheduled for the remainder of 2026: ## **1. Q1 2026 Earnings Season (May)** The top holdings in MSOS—the major Multi-State Operators (MSOs)—are scheduled to report their first-quarter results in early May. These calls will likely focus on "Day 1" impacts of the recent medical rescheduling and updated guidance on **Section 280E** tax savings. * **Curaleaf (CURLF):** May 5, 2026 * **Trulieve (TCNNF):** May 7, 2026 * **Green Thumb (GTBIF) / Verano (VRNOF):** Expected mid-May 2026 ## **2. Broader Rescheduling Hearings (June – July)** While the Department of Justice (DOJ) finalized the move of **medical cannabis** to Schedule III on April 23, 2026, a second, more significant phase is now in motion: * **June 29, 2026:** An expedited administrative hearing begins to consider reclassifying **all** marijuana (including adult-use/recreational) to Schedule III. * **July 15, 2026:** The mandated deadline for this hearing to conclude. A positive outcome here would theoretically apply federal tax relief to the entire revenue stream of MSOs, not just the medical portion. ## **3. The "Hemp Cliff" (November 12, 2026)** The **Continuing Appropriations and Extensions Act of 2026 (CAEA)** contains a "strict reinterpretation" of hemp that is a major tailwind for MSOs. * **The Impact:** This law narrows the definition of legal hemp, effectively banning many psychoactive hemp-derived products (like Delta-8) that have competed with licensed dispensaries. * **The Catalyst:** This is expected to drive significant market share back to the MSOs held within the MSOS ETF by removing "gray market" competition. ## **4. Uplisting & Institutional Inflows** With the finalization of Schedule III, the "custody hurdle" for major banks and institutional investors is beginning to lower. * **Exchange Uplisting:** Investors are watching for any moves by the TSX or potentially U.S. exchanges (NYSE/NASDAQ) to allow MSOs to uplist. * **SAFER Banking Act:** While rescheduling provides the regulatory framework, the passage of the SAFER Banking Act remains the primary "missing link" for full U.S. exchange access and traditional credit card processing. > **Note on 280E Relief:** Analysts estimate that the full implementation of Schedule III could improve EBITDA margins for major MSOs by **10–20 percentage points** due to the removal of the 280E tax penalty, which currently prevents cannabis businesses from deducting standard operating expenses. > What specific aspect of the MSOS holdings are you tracking most closely right now—is it the regulatory side or the technical price action?

SwordfishOk504

Sigh. Because codeine is not illegal. You guys all keep looking at other *legal* products under Schedule III and assuming that means anything in Schedule III is legal. That's not the case. For crying out loud, there are so many experts and articles and lawyers who have explained this repeatedly.

Weak_Emu3659

# FINAL FANTASY III Music Special Live Stream✨ [https://www.youtube.com/watch?v=X78OZIWT7pQ](https://www.youtube.com/watch?v=X78OZIWT7pQ)

Mattagascar

280e itself does not distinguish between how the products are marketed or sold. The rescheduling is to reschedule marijuana to schedule 3. The current order that came out last week was not the last of rescheduling in this process, and rescheduling will be for marijuana generally speaking, not “medical vs recreational”. I don’t think the final rule for rescheduling will bifurcate between medical vs recreational. Rescheduling to schedule III still “only legitimizes medical”; But even if it somehow does have some weird “medical is schedule iii but illicit sales remain schedule i” this won’t hold up to scrutiny as it pertains to the plain reading of 280e.

Kbarbs4421

I'm honestly not trying to argue in circles with you. But I'm still not convinced my read of this is wrong. The Final Order issued last week moved state licensed med cannabis to Schedule III. Odd bifurcation, yes. But still, that is immediately binding as far as I understand it. Which means medical cannabis distributed through federally approved channels and sold by a state licensed operator that is properly registered with the DEA would be legal. The upcoming rulemaking process for cannabis ***writ large*** is not essential to med rescheduling. It could stall or fail and the med reschedule would survive. Again, my understanding; not some deep legal analysis. Very much open to being proven wrong. I'm just trying to unravel the rats nest here.

Silver_Variety_1108

$SLS 20 different cancers rely on 1 pathway to stay alive. Disrupt that pathway, many, many people live much longer and many cured! GPS Regal phase III has gone on much longer than expected. That’s a very good sign that people are living longer!

Kbarbs4421

> The April 23 “rescheduling” was done by the DOJ. They do not have the power to make changes at the federal level. So this week’s “rescheduling” was more symbolic, The DOJ doesn't have the power to make changes at the federal level?! Please explain. And the rescheduling action last week was symbolic?! That is not my understanding. Pretty sure it's the exact opposite. Med cannabis is now rescheduled, officially not symbolically. A legal challenge may arise that could reverse that action. But unless/until.that happens, med cannabis is Schedule III. That's now the law.of the land. Nothing symbolic about it. > That may be enough to loosen regulations around 280e, banking and US exchanges. We will see. Agreed that banking and uplisting is still a tbd. But it's inarguable that 280E is no longer applicable to state licensed med cannabis sales, assuming the operator is properly registered with FDA. > Technically all cannabis is still schedule 1 at the federal level, despite the April 23 announcement, as only congress can make changes to the controlled substance act. This has not happened yet. Untrue. Congress does not need.to act.to reschedule. Technically, med cannabis is officially rescheduled. Please show me a competent source saying otherwise on either of these claims? > TLDR: state medical is “functionally” legal, but “technically” still federally illegal by law since it has not gone through the proper legal process. I'm fairly certain this is invented logic. Is this your own take? Or are you basing this on compaletent, authoritative legal analysis? I've not seen anyone else making such claims.

King_Chron

The idea that Glass House is a guaranteed winner under interstate commerce overlooks the major legal and operational barriers they face. Even if federal borders open for medical trade, Glass House lacks the operational footprint or distribution facilities to sell outside California, where they are currently stuck in a single, oversaturated market. They don't have existing wholesale agreements with the multi-state operators who own the dispensaries in other states, and those companies have every incentive to protect their own in-state cultivation rather than carry an outsider’s cheap flower. Furthermore, the recent Schedule III reclassification only applies to medical cannabis, while Glass House’s business model and top brands are predominantly geared toward the recreational market. With broader recreational rescheduling still tied up in administrative hearings until at least late June, their path to becoming a national player is currently based on a hypothetical outcome rather than actual business deals or a clear legal lane.

Total_Schedule591

Arthritis III

Imaginary_Rooster622

Based on the April 2026 U.S. Department of Justice (DOJ) order rescheduling marijuana to Schedule III, state-licensed medical cannabis companies are now required to register with the DEA, though an expedited pathway has been created for them. +1 Key Details for State-Licensed Entities (As of April 2026): Registration Requirement: State-licensed medical marijuana entities (cultivators, processors, and dispensaries) must register with the DEA as "practitioners" or manufacturers under 21 U.S.C. § 823(g). Expedited Pathway: The DEA provides an expedited registration process where state licensees can submit their existing state credentials as "conclusive evidence of state authorization" to receive federal registration. Deadline: State medical marijuana licensees who submit applications within 60 days of the publication of the final order (by roughly late June 2026) may continue to operate under their state licenses while the DEA reviews their application. * " to receive federal registration" * I'm going to take a leap and suggest that if a medical cannabis company has received federal registration then the US exchanges will allow them to Uplist What are your thoughts on this?

ENTRAPM3NT

The sector has been moving on federal reform catalysts. Big one is Schedule III rescheduling. If finalized it could remove 280E tax burdens for U.S. operators, which would be a major boost to profitability and is why a lot of weed stocks reacted so hard. There is also growing attention on banking reform, which could improve access to capital and lower risk for the sector. For U.S. MSOs this is mostly about fundamentals improving. For companies like Tilray it is partly sector sympathy and partly long term optionality if U.S. doors open further. Going forward most people are watching the June 29 hearing, whether banking reform gains traction, and whether the market starts repricing cannabis names based on improved earnings potential. Near term I would expect volatility more than a straight line up. These names often run on headlines and then pull back. Bull case is rescheduling progresses, 280E relief hits, banking follows, and the whole sector rerates higher. Risk is delays or political/regulatory stalling. Overall recent news was materially positive for the sector, but probably more important for long term fundamentals than immediate moonshot price action.

IdratherBhiking1

l😂 When I intend to make a speculative investment / swing trade off a bottom in a company after researching the fundamentals, financials, and identify a technical bottoming pattern with daily/ weekly// monthly RSI oversold… Then the price 3x’s in a few weeks and take profit because you know there is no substantial support to catch the sell off…. Then watch price go below book value yet again and RSI back to oversold…. Signed contracts (albeit minor) to utilize existing AI infrastructure with Dell, an Ivy Leavue school in Columbia, and a robotics company… Aaaand have a fully funded tier III+ data center in development…. It seems reasonable to invest the profit and a bit more in HIVE…. But yeah. I know why you would question the trade / investment. HIVE has been a complete and total pile of 💩. Yes…. Diluted shareholders by 65% between 2025 to early 2026. That why i didn’t buy in. (Learned about the company a few years ago. One of (if not the first) Bitcoin mining companies. I was researching XRP and the SEC case. Frank Holmes (CEO) was an outspoken XRP critic…. The thesis in investing now- if you sold HIVE’s current aseets, you would get the current market cap. The data center is not priced in . Signing contracts… Sometimes everything is so bad (and that bad is priced into the market capi), it’s actually a really good entry into a speculative investment.. It helps that institutional investment is higher than it has ever been…. I am watching for any sign of institutional selling and the cash burn closely because it is dangerous….

IdratherBhiking1

I’m not the OP, but I am invested in HIVE. Not an oppositional reply to you Ryan. (My name is also Ryan). I keep wondering why people keep saying this about HIVE. People were saying the same thing about RKLB when I posted about it at 4.50 a share…. I’m also not trying to sell you on it. It doesn’t matter if you or every member on this sub buys. We are along for the ride. Institutions drive the share price. Anyway…. There are literally almost no bag holders… 70-90% of owned shares are profitable based on the 10 cent uo and down as share price consolidates at this price… I’d show you, but i cant reply with an image of the data. If you want to see why i am invested, if you are at all interested in a high risk / reward investment…. I don’t see it as high risk, but thats not the point… Take a minute to look into what a Tier III+ data center is…. Then take a look at current price to book value iof HIVE. (To save you one minute, It’s just over 1). If you don’t know what book value is- it’s the value of current assets minus liabilities and debt. Current market cap is around 600 mil. Just consider what an operational Tier III+ data would add to book value…. The data center is paid for… Institutional ownership is at all time high and increasing. They just held an offering exclusive to institutional investors. That has already been priced in…. Was originally set to 75 mil. Was upsized to 115$ mil due to demand… I like making money. I know I will on hive. Check my post history…. Go back to RKLB if you don’t believe me:

IdratherBhiking1

I’m not the OP, but I am invested in HIVE. Not an oppositional reply to you Ryan. (My name is also Ryan). I keep wondering why people keep saying this about HIVE. People were saying the same thing about RKLB when I posted about it at 4.50 a share…. I’m also not trying to sell you on it. It doesn’t matter if you or every member on this sub buys. We are along for the ride. Institutions drive the bus…. Anyway…. There are literally almost no bag holders… 70-90% of owned shares are profitable based on the 10 cent uo and down as share price consolidates at this price… I’d show you, but i cant reply with an image of the data. If you want to see why i am invested, if you are at all interested in a high risk / reward investment…. I don’t see it as high risk, but thats not the point… Take a minute to look into what a Tier III+ data center is…. Then take a look at current price to book value iof HIVE. (To save you one minute, It’s just over 1). If you don’t know what book value is- it’s the value of current assets minus liabilities and debt. Current market cap is around 600 mil. Just consider what an operational Tier III+ data would add to book value…. The data center is paid for… Institutional ownership is at all time high and increasing. They just held an offering exclusive to institutional investors. That has already been priced in…. Was originally set to 75 mil. Was upsized to 115$ mil due to demand… I like making money. I know I will on hive. Check my post history…. Go back to RKLB if you don’t believe me:

Zephod03

A dem wouldn't have worded it so that only the approved FDA medical products get schedule III meaning that recreational or anyone not corporate approved still has to contend with the old laws. If people like you weren't so easy to dupe, Repubs would never win anything past a prison sentence.

King_Chron

Based on its [Full Year 2025 financial results](https://ir.marimedinc.com/news-events/press-releases/detail/296/marimed-reports-fourth-quarter-and-full-year-2025-earnings) (released March 11, 2026) and current 2026 analyst projections, the removal of Section 280E following the federal shift to Schedule III is expected to save **MariMed Inc. (MRMD)** approximately **$15 million annually**. This saving represents **9.4% of its total revenue** ($159.8M).  **MariMed Post-280E Breakdown** * **Profitability Flip**: In 2025, MariMed reported a **GAAP net loss of $14.5 million**. Under a standard 21% corporate tax regime, analysts project this loss will flip to a **net profit of $5 million to $10 million** in 2026, **even without revenue growth.** * **Operating Expense Deductions**: MariMed will finally be able to deduct its **$56.9 million in annual operating expenses**—including rent, payroll, and marketing—against its federal taxes. * **Effective Tax Rate**: The company’s effective tax rate is expected to drop from a staggering **70%–90%** of gross profit to a normalized **\~21%** of net income. * **Free Cash Flow (FCF)**: Analysts at [Matrix BCG](https://matrixbcg.com/blogs/growth-strategy/marimedinc) project a **$3 million to $10 million FCF upside** from 280E removal, which the company intends to use to fund expansion in Maryland, Ohio, and Illinois. * **Valuation Rerating**: Beyond immediate cash, the removal of the tax "overhang" is estimated to add **$0.34 to $0.55 per share** in value, potentially raising the company's price target toward **$0.90 – $0.95 USD**.  [MatrixBCG.com](http://MatrixBCG.com) \+8 Dont let the nay sayers steer you away from this one.

wallstreetdegen6969

pls big yahu if you hear me right now, make $SPY turn into Artemis III

LandStander420

It was absolutely legal and it cannot be undone. Schedule III for state run medical is edged in stone.

ENTRAPM3NT

Because the June 29 hearing now appears to have a July 15 conclusion, the timeline looks materially compressed versus prior expectations. If the hearing closes in July and a final rule follows in the typical post-hearing window, that points toward Schedule III action in Q3–Q4 2026 rather than 2027. It’s not absolute certainty, but the procedural path now makes 2026 the higher-probability outcome.

ENTRAPM3NT

You said rec s3? You keep saying not a done deal, but I never argued certainty. I said odds improved. And if we’re strictly talking Schedule III/280E, your earlier point about skepticism toward recreational use is even less relevant, because 280E relief flows from medical rescheduling, not federal adult-use legalization.

ENTRAPM3NT

You just made my point. if Trump’s stance is consistent with medical rescheduling, then his skepticism of recreational use isn’t an argument against Schedule III. Those are different lanes. Clearly a lot has changed since he said that as well.

ENTRAPM3NT

Your logic only works if Schedule III = recreational legalization, and it doesn’t. They’re separate. Trump expressing support for medical is actually more consistent with rescheduling than blocking it.

ENTRAPM3NT

Rescheduling to Schedule III isn’t about Trump liking rec, it’s a federal medical/scientific administrative process already in motion. Yesterday’s developments increased odds because they signaled momentum and political willingness to let that process conclude in 2026. Also, Schedule III itself doesn’t legalize adult-use cannabis, so opposition to recreational use isn’t really an argument against rescheduling

Imaginary_Rooster622

Good morning 🌅 No more 280E When is the new ALJ hearing on Rescheduling Cannabis? The new Drug Enforcement Administration (DEA) administrative law judge (ALJ) hearing regarding the broader rescheduling of cannabis to Schedule III is scheduled to begin on June 29, 2026. +2 Key details regarding this new hearing include: Duration: The hearing is expected to run from June 29, 2026, and conclude no later than July 15, 2026. Purpose: This hearing will address the rescheduling of all cannabis (including adult-use) to Schedule III. Scope: The hearing will use the same proposed rule published in the Federal Register in May 2024. Background: This new, expedited hearing replaces the previously stalled hearing process that was slated for January 2025. Immediate Action: Separately, as of April 23, 2026, the DOJ has already rescheduled FDA-approved and state-licensed medical cannabis to Schedule III. Cannabis Business Times Cannabis Business Times +5 The hearing is intended to provide a legally compliant pathway for the broader rescheduling, with a potential final rule expected in late 2026 or early 2027. Cannabis Business Times +1

SuzyCreamcheezies

Schedule III drugs under the Controlled Substances Act are defined as having a currently accepted medical use in treatment. That means that cannabis under S3 is regulated for medical use only. In no way does schedule 3 allow for recreational use. That would require full legalization or decriminalization.

SuzyCreamcheezies

Schedule III drugs under the Controlled Substances Act are defined as having a currently accepted medical use in treatment. That means that cannabis under S3 is regulated for medical use only. In no way does schedule 3 allow for recreational use. That would require full legalization or decriminalization. You are conflating state and federal regulations. They are different. Just because state laws allow recreational cannabis does not mean federal does, since they have only moved cannabis to schedule 3.

SuzyCreamcheezies

Schedule III drugs under the Controlled Substances Act are defined as having a currently accepted medical use in treatment. That means that cannabis under S3 is regulated for medical use only. In no way does schedule 3 allow for recreational use. That would require full legalization or decriminalization. You are conflating state level regulations with federal. They are not the same.

SuzyCreamcheezies

Schedule III drugs under the Controlled Substances Act are defined as having a currently accepted medical use in treatment. That means that cannabis under S3 is regulated for medical use only. In no way does schedule 3 allow for recreational use. That would require full legalization or decriminalization.

SuzyCreamcheezies

Schedule III drugs under the Controlled Substances Act are defined as having a currently accepted medical use in treatment. That means that cannabis under S3 is regulated for medical use only. In no way does schedule 3 allow for recreational use. That would require full legalization or decriminalization.

snark42

Well I stand corrected, but it's because it's not really schedule III yet? Lots of missing info on this. > Under an order from Acting Attorney General Todd Blanche, marijuana regulated by a state medical cannabis license will immediately move to Schedule III. Marijuana products such as those in state-legal recreational markets remain in Schedule I for now, however, subject to a hearing process this summer to consider broader rescheduling of cannabis. https://www.marijuanamoment.net/feds-announce-marijuana-industry-tax-guidance-is-coming-as-rescheduling-takes-effect/

AverageNo130

Under an order signed by Blanche, marijuana products regulated by a state medical cannabis license will immediately move to Schedule III, as will any marijuana products that are approved by the Food and Drug Administration (FDA). Then, beginning on June 29, there will be a new expedited administrative hearing process to consider the broader rescheduling of cannabis from Schedule I to Schedule III. The Federal Register filing on the hearing says it “will conclude not later than July 15.” MM

palindromic

*I’m into having sex I ain’t into making love.. some come give me a hug.* -Curtis James “50 cent” Jackson III